AbCellera Biologics (ABCL) Current Deferred Revenue (2020 - 2026)

AbCellera Biologics has reported Current Deferred Revenue for 7 years, with the latest figure at $7.7 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 76.2% year-over-year to $7.7 million; the trailing twelve-month figure through Mar 2026 stood at $7.7 million (down 76.2% YoY), and the FY2025 full-year result was $17.0 million, down 11.42% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $7.7 million, down from $17.0 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $37.2 million in Q1 2023, with the low at $7.7 million in Q1 2026.
• Historically, Current Deferred Revenue has averaged $24.8 million across 5 years, with a median of $27.2 million in 2023.
• Annual changes were most pronounced in 2025 — Current Deferred Revenue jumped 98.89% — and 2026, when it plunged 76.2%.
• AbCellera Biologics' Current Deferred Revenue stood at $14.3 million in 2022, then jumped by 89.88% to $27.2 million in 2023, then fell by 29.21% to $19.2 million in 2024, then decreased by 11.42% to $17.0 million in 2025, then slumped by 54.52% to $7.7 million in 2026.
• The last three Current Deferred Revenue figures came in at $7.7 million (Q1 2026), $17.0 million (Q4 2025), and $21.5 million (Q3 2025), per Business Quant data.